The anti-NASH mechanism was regarded to involve DMTHB, which could target the NLRP3 inflammasome to suppress NLRP3 inflammasome activation (Zhang et al., 2021). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.